Skip to content
OpenCapital
Get started

Agios Pharmaceuticals AGIO Q4 2025 Annual earnings

Reported February 12, 2026 · Before market open

Revenue$20.0MBeat by $7.9M
EPS-$1.85Beat by $0.12
Revenue estimate$12.1M
EPS estimate-$1.97

Next report

Jul 30, 2026 (Tomorrow)
Revenue estimate$26.4M
EPS estimate-$1.65

Financials

Q4 2025

Income statement

See full
Revenue$20.0M+86.1%
Gross profit$18.1M+91.0%
Operating income-$121.6M+2.8%
Net income-$108.0M—
EPS (diluted)-$1.85—

Balance sheet

See full
Cash & equivalents$89.1M+16.9%
Total debt$40.2M-29.4%
Total equity$1.2B-22.6%
Total assets$1.3B-22.0%

Cash flow

See full
Operating cash flow-$96.2M+27.8%
CapEx$1.1M+15.8%
Free cash flow-$97.3M+27.4%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$1.59B-15.3%
Enterprise value$1.54B-17.1%
P/S29.4×-22.0×

Profitability

See full
Gross margin88.3%-0.3pp
Operating margin-873.9%-175pp
Net margin-764%—
FCF margin-698.3%-181pp

Returns & leverage

See full
Return on equity-30.2%—
Debt / equity0×0.0×
Current ratio11.5×-0.4×

Versus estimates

Revenue

Q1 2026$20.7MBeat by $7.4M
Q4 2025$20.0MBeat by $7.9M
Q3 2025$12.9MBeat by $1.2MQ2 2025$12.5MBeat by $2.2MQ1 2025$8.7MMiss by $1.3MQ4 2024$10.7MBeat by $1.4M

Diluted EPS

Q1 2026-$1.69Beat by $0.12
Q4 2025-$1.85Beat by $0.12
Q3 2025-$1.78Beat by $0.15Q2 2025-$1.93Miss by $0.19Q1 2025-$1.55Beat by $0.25Q4 2024-$1.74Miss by $0.05

Ask the moment Agios Pharmaceuticals reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Agios Pharmaceuticals report Q4 2025 earnings?
Agios Pharmaceuticals (AGIO) reported Q4 2025 earnings on February 12, 2026 before market open.
What were Agios Pharmaceuticals's Q4 2025 revenue and EPS?
Agios Pharmaceuticals reported revenue of $20.0M and eps of $-1.85 for Q4 2025.
Did Agios Pharmaceuticals beat estimates in Q4 2025?
Revenue beat the consensus estimate of $12.1M by $7.9M. EPS beat the consensus estimate of $-1.97 by $0.12.
How did Agios Pharmaceuticals's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 86.1% from $10.7M a year earlier and eps declined 6.3% from $-1.74.
Where can I find Agios Pharmaceuticals's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001439222-26-000023) and the 10-K periodic report (0001439222-26-000025) directly on SEC EDGAR. The filing index links above go to sec.gov.